Table 13.I.
FDA-approved anti-metastatic drugs reported with own mechanism of action and specific anti- metastasis application.
| Commercial name | Drug | Mechanism of action (MOA) | Application | FDA-approval year |
|---|---|---|---|---|
| Lonsurf
(Taiho Pharmaceutical Co., Ltd) |
Trifluridine/Tipiracil | Inhibits DNA synthesis and further cellular proliferation | Metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma | 2019 |
| Keytruda (Merck) | Pembrolizumab | Binds to the PD-1 receptor, blocking both immune-suppressing ligands, PDL1 and PDL2, from interacting with PD-1 to help restore T-cell response and immune response | Previously treated metastatic small cell lung cancer and recurrent oesophageal cancer with PD-L1 expressing tumours; metastatic or unresectable recurrent HNSCC | 2019 |
| Rozlytrek (Roche) | Entrectinib | Block ROS-1 and NTRK kinase activity inducing death of cancer cell | ROS1-positive, metastatic NSCLC | 2019 |
| Lorbrena (Pfizer) | Lorlatinib | ALK-tyrosine kinase inhibitor (TKI) | ALK-positive metastatic non-small cell lung cancer | 2018 |
| Vizimpro (Pfizer) | Dacomtinib | EGFR kinase inhibitor | Metastatic NSCLC | 2018 |
| Alunbrig
(Ariad Pharmaceuticals) |
Brigatinib | ALK/IGF-1R/FLT-3 TKI | Advanced ALK-positive metastatic non-small cell lung cancer | 2017 |
| Opdivo
(Bristol-Myers Squibb) |
Nivolumab | Binds to the PD-1 receptor, blocking both immune-suppressing ligands, PDL1 and PDL2, from interacting with PD-1 to help restore T-cell response and immune response | Recurrent or metastatic HNSCC | 2017 |